Literaturangaben

Zeitschrift für Infektionstherapie 2.2024

Übersicht

Update zur Therapie der diabetischen Fußinfektion (S.14)

1.    Senneville É. et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clin Infect Dis. 2023; published online first Oct 2, 2023. doi: 10.1093/cid/ciad527.
  
2.    El Sahly H. M. Diagnosis and Management of Diabetes-Related Foot Infections. NEJM Journal Watch; reviewing Senneville É. et al. Clin Infect Dis. 2023, Oct 2 2023. doi: 10.1093/cid/ciad/527. URL: https://www.jwatch.org/na56648/2023/11/06/diagnosis-and-management-diabetes-related-foot-infections [4.4.2024]
  
3.    IWGDF/IDSA. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes.

URL: https://iwgdfguidelines.org/infection-guideline-2023/ [4.4.2024]

Reiseimpfungen: Dengue – Ein Neuer im Team der Reisemedizin (S. 17)

1.    Arbeitskreises Blut des Bundesministeriums für Gesundheit und Soziale Sicherung. Arboviren – durch Arthropoden übertragbare Viren. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2004; 47: 910-918. doi: 10.1007/s00103-004-0890-8.

2.    Mustafa MS, Rasotgi V, Jain S, Gupta V. Discovery of fifth serotype of dengue virus (DENV-5): a new public health dilemma in dengue control. Med J Armed Forces India 2015; 71(1): 67-70. doi: 10.1016/j.mjafi.2014.09.011.

3.    Simmons CP, Farrar JJ, Nguyen vVC, Wills B. Dengue. New Engl J Med 2012; 366(15): 1423-1432. doi: 10.1056/NEJMra1110265.

4.    Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet 2019; 393(10169): 350-363. doi: 10.1016/S0140-6736(18)32560-1.

5.    World Health Organization. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

6.    Dammermann W, Haller IE, Singethan K, Vinnemeier CD, Hentschel F. Asymptomatic arbovirus and campylobacter infections in German travelers to Asia. Arch Virol 2023; 168(10): 254. doi: 10.1007/s00705-023-05870-y.

7.    Huits R, Angelo KM, Amatya B, Barkati S, Barnett ED, Bottieau E, Emetulu H, Epelboin L, Eperon G, Medebb L, Gobbi F, Grobusch MP, Itani O, Jordan S, Kelly P, Leder K, Díaz-Menéndez M, Okumura N, Rizwan A, Rothe C, Saio M, Waggoner J, Yoshimura Y, Libman M, Hamer DH, Schwartz E. Clinical characteristics and outcomes among travelers with severe dengue: a GeoSentinel analysis. Ann Intern Med 2023; 176(7): 940-948. doi: 10.7326/M23-0721.

8.    Robert Koch Institut. https://survstat.rki.de/Content/Query/Create.aspx (Stand: 16.11.2022)

9.    Falkenhorst G, Enkelmann J, Frank C, Lachmann R, Faber M, Pörtner K, Stark K: Zur Situation bei wichtigen Infektionskrankheiten – Reiseassoziierte Krankheiten 2019. Epidem Bull 2020; 50: 7-20. doi: 10.25646/7693.

10.    Bellini R, Michaelakis A, Petrić D, Schaffner F, Alten B, Angelini P, Aranda C, Becker N, Carrieri M, Di Luca M, Fălcuţă E, Flacio E, Klobučar A, Lagneau C, Merdić E, Mikov O, Pajovic I, Papachristos D, Sousa CA, Stroo A, Toma L, Vasquez MI, Velo E, Venturelli C, Zgomba M. Practical management plan for invasive mosquito species in Europe: I. Asian tiger mosquito (Aedes albopictus). Travel Med Infect Dis. 2020; 35: 101691. doi: 10.1016/j.tmaid.2020.101691.

11.    Frank C, Offergeld R, Lachmann R, Stark K, Schmidt-Chanasit J. Saison stechmückenübertragener Krankheitserreger beginnt. Epidem Bull 2023; 22: 3-7. doi: 10.25646/11492.

12.    European Centre for Disease Prevention and Control (ECDC). Autochthonous vectorial transmission of dengue virus in mainland EU/EEA, 2010-present. https://www.ecdc.europa.eu/en/all-topics-z/dengue/surveillance-and-disease-data/autochthonous-transmission-dengue-virus-eueea (Stand: 15.11.2023)

13.    Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Klobucar A, Pem-Novosel I, Kurecic-Filipovic S, Komparak S, Martic R, Duricic S, Betica-Radic L, Okmadzic J, Vilibic-Cavlek T, Babic-Erceg A, Turkovic B, Avsic-Zupanc T, Radic I, Ljubic M, Sarac K, Benic N, Mlinaric-Galinovic G. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill 2011, 16: 19805. doi: 10.2807/ese.16.09.19805-en.

14.    Pem-Novosel I, Vilibic-Cavlek T, Gjenero-Margan I, Kaic B, Babic-Erceg A, Merdic E, Medic A, Ljubic M, Pahor D, Erceg M. Dengue virus infection in Croatia: seroprevalence and entomological study. New Microbiol 2015; 38(1): 97-100.

15.    Paul-Ehrlich-Institut. Denguefieber-Impfstoffe. https://www.pei.de/DE/arzneimittel/impfstoffe/denguefieber/dengue-node.html (Stand: 15.11.2023)

16.    World Health Organization. Dengue vaccine: WHO position paper – September 2018. Wkly Epidemiol Rec 2018; 93: 457-476.

17.    Halstead SB, Dans LF. Dengue infection and advances in dengue vaccines for children. Lancet Child Adolens Health 2019; 3(10): 734-741. doi: 10.1016/S2352-4642(19)30205-6.

18.    Takeda GmbH. Fachinformation Qdenga®. https://www.takeda-produkte.de/system/files/produkt-info/fachinformation-qdengar.pdf (Stand: Dezember 2022)

19.    Rivera L, Biswal S, Sáez-Llorens X, Reynales H, López-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, Yu D, Watanaveeradej V, Espinoza F, Dietze R, Fernando L, Wickramasinghe P, Duarte MoreiraJr E, Fernando AD, Gunasekera D, Luz K, Venâncioda Cunha R, Rauscher M, Zent O, Liu M, Hoffman E, LeFevre I, Tricou V, Wallace D, Alera M, Borkowski A. Three-year efficacy and safety of Takeda's Dengue vaccine Candidate (TAK-003). Clin Infect Dis 2022; 75(1): 107-117. doi: 10.1093/cid/ciab864.

20.    https://clinicaltrials.gov/study/NCT02747927

21.    Tricou V, Winkle PJ, Tharenos LM, Rauscher M, Escudero I, Hoffman E, LeFevre I, Borkowski A, Wallace D. Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults. Vaccine 2023; 41(47): 6999-7006. doi: 10.1016/j.vaccine.2023.09.049.

22.    https://clinicaltrials.gov/study/NCT03423173

23.    Tricou V, Essink B, Ervin JE, Turner M, Escudero I, Rauscher M, Brose M, Lefevre I, Borkowski A, Wallace D. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLoS Negl Trop Dis 2023; 17(3): e0011124. doi: 10.1371/journal.pntd.0011124.

24.    Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, Mandaric S, Rauscher M, Brose M, Lefevre I, Folschweiller N, Wallace D. A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country. Vaccine 2023; 41(7): 1398-1407. doi: 10.1016/j.vaccine.2023.01.007.

25.    Kling K, Külper-Schiek W, Schmidt-Chanasit J, Stratil J, Bogdan C, Ramharter M, Rieke B, Wichmann O, Burchard G: STIKO-Empfehlung und wissenschaftliche Begründung der STIKO zur Impfung gegen Dengue mit dem Impfstoff Qdenga. Epidem Bull 2023; 48: 3-43. doi: 10.25646/11784.

26.    Takeda Pharmaceutical Company Limited. https://www.takeda.com/newsroom/statements/2023/takeda-announces-voluntary-withdrawal-of-US-biologics-license-application-for-dengue-vaccine-candidate-TAK-003/ (Stand: 11.07.2023)